The estimated Net Worth of Girish N Aakalu is at least $802 mil dollars as of 4 April 2022. Mr. Aakalu owns over 963 units of Genocea Biosciences Inc stock worth over $0 and over the last 6 years he sold GNCA stock worth over $3,840. In addition, he makes $798,058 as Chief Business Officer at Genocea Biosciences Inc.
Girish has made over 2 trades of the Genocea Biosciences Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 963 units of GNCA stock worth $1,204 on 4 April 2022.
The largest trade he's ever made was selling 2,397 units of Genocea Biosciences Inc stock on 15 March 2022 worth over $2,637. On average, Girish trades about 480 units every 3 days since 2018. As of 4 April 2022 he still owns at least 74,459 units of Genocea Biosciences Inc stock.
You can see the complete history of Mr. Aakalu stock trades at the bottom of the page.
Girish N. Aakalu Ph.D. serves as Chief Business Officer of the Company. Dr. Girish joined Genocea in December 2018 as Chief Business Officer. In this role, he leads Genocea’s business development efforts. His broad skill set spans business development, corporate and R&D strategy, product portfolio management, commercial planning, and alliance management. Prior to joining Genocea, Girish was employed by the Ipsen Group, from May 2015 until December 2018, where he was most recently Vice President: Global Head of External Innovation, and Pfizer, Inc., from October 2007 until May 2015, where he held the title of Executive Director: Head of Strategy, Innovation & Operations for Pfizer’s External R&D Innovation team prior to his departure. His previous roles also include business development and oncology pipeline market planning positions at Genentech, Inc. and life science consulting experience at L.E.K Consulting. He received a B.A. in Biophysics with General and Departmental Honors from Johns Hopkins University, a Ph.D. in Cellular and Molecular Neurobiology following an M.S. in Biology from the California Institute of Technology and has completed executive education in Corporate Governance at Northwestern University - Kellogg School of Management.
As the Chief Business Officer of Genocea Biosciences Inc, the total compensation of Girish Aakalu at Genocea Biosciences Inc is $798,058. There are 2 executives at Genocea Biosciences Inc getting paid more, with William Clark having the highest compensation of $1,063,000.
Girish Aakalu is 45, he's been the Chief Business Officer of Genocea Biosciences Inc since 2018. There are 17 older and 1 younger executives at Genocea Biosciences Inc. The oldest executive at Genocea Biosciences Inc is George Siber, 75, who is the Independent Director.
Girish's mailing address filed with the SEC is 100 Acorn Park Dr 5th floor, Cambridge, MA 02140, USA.
Over the last 11 years, insiders at Genocea Biosciences Inc have traded over $9,875,933 worth of Genocea Biosciences Inc stock and bought 177,421,644 units worth $259,728,894 . The most active insiders traders include Forest Baskett, Scott D Sandell y Anthony A. Jr. Florence. On average, Genocea Biosciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $0. The most recent stock trade was executed by Diantha Duvall on 2 June 2022, trading 1,355 units of GNCA stock currently worth $81.
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Genocea Biosciences Inc executives and other stock owners filed with the SEC include: